> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS Psoriasis Drug Posts Favorable Trial Results
- URL: https://www.fdaweb.com/bms-psoriasis-drug-posts-favorable-trial-results/
- Published: 2020-11-04T12:00:00.000Z
- Updated: 2026-09-14T16:35:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148022

Bristol Myers Squibb has announced positive results from POETYK PSO-1, a pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 inhibitor for treating patients with moderate to severe plaque psoriasis. POETYK PSO-1 evaluated 6 mg of deucravacitinib once daily and it met both co-primary endpoints versus placebo, with more patients achieving favorable psoriasis scores after 16 weeks of treatment with deucravacitinib, the company says. The trial also met multiple key secondary endpoints, including showing deucravacitinib was superior to Amgen’s Otezla (apremilast) in the proportion of patients reaching a target psoriasis score at week 16\. The overall safety profile of deucravacitinib in the POETYK PSO-1 trial was consistent with previously reported Phase 2 results, Amgen says.

The trial data and detailed results will be shared at a future medical meeting, Amgen says. “POETYK PSO-1 is the first of two global Phase 3 studies designed to evaluate safety and efficacy of deucravacitinib compared to placebo and Otezla in patients with moderate to severe plaque psoriasis,” it says. “Results from the second study, POETYK PSO-2, are expected in the first quarter of 2021.”